Brief: EMA Recommends Revoking Marketing Authorisation For Tavneos In EU

Amgen

26/06/2026 11:50

June 26 (Reuters) - EMA:
EMA - RECOMMENDS REVOKING MARKETING AUTHORISATION FOR TAVNEOS IN THE EU
EMA - REVIEW OF TAVNEOS INITIATED OVER DATA INTEGRITY CONCERNS IN ADVOCATE STUDY
EMA - FINDS ADVOCATE STUDY FOR TAVNEOS BREACHED GOOD CLINICAL PRACTICE PRINCIPLES
EMA - RECOMMENDS NO NEW PATIENTS START TAVNEOS; SWITCH EXISTING PATIENTS TO ALTERNATIVES
EMA - WARNS OF SERIOUS LIVER RISKS WITH TAVNEOS; RECOMMENDS CLOSE MONITORING
EMA - STATES TAVNEOS STUDY DATA INCORRECT AND UNRELIABLE FOR EFFECTIVENESS
Further company coverage: AMGN.O

 ((Reuters.Briefs@thomsonreuters.com;))